Literature DB >> 14514578

Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes.

Ake Tenerz1, Anna Norhammar, Angela Silveira, Anders Hamsten, Göran Nilsson, Lars Rydén, Klas Malmberg.   

Abstract

OBJECTIVE: Individuals with diabetes have an increased morbidity from acute myocardial infarction (AMI). Based on an oral glucose tolerance test (OGTT), 40-45% of patients with AMI have diabetes. The objective of this study was to characterize the glucometabolic profile of patients with AMI without known diabetes and to see if sustained glucometabolic perturbations are predictable during the hospital phase of the disease. RESEARCH DESIGN AND METHODS: A total of 145 patients with AMI and no previous diagnosis of diabetes were subjected to an OGTT at hospital discharge and 3 months thereafter. Based on the OGTT after 3 months, they were defined as having normal glucose tolerance (NGT; n = 50), impaired glucose tolerance (IGT; n = 59), or diabetes (n = 36). Components of the metabolic syndrome, including insulin resistance assessed by homeostasis model assessment (HOMA-IR), were recorded.
RESULTS: Patients with AMI had no changes in insulin resistance from hospital discharge to follow-up. An OGTT and/or a single blood glucose taken 60 min (BG-60) after ingestion of 75 g glucose at hospital discharge were predictors of the outcome of the OGTT at follow-up. With a cutoff value for BG-60 of 8.6 mmol/l, 70% of the patients were correctly predicted as either belonging to the NGT group or the IGT/diabetes group after 3 months. Age, BMI, antihypertensive treatment, HbA(1c), fasting blood glucose, blood lipids, insulin, proinsulin, HOMA-IR, and plasminogen activator inhibitor 1 did not add predictive power.
CONCLUSIONS: Patients with AMI and no previous diagnosis of diabetes have no changes in insulin resistance from hospital discharge to a 3-month follow-up. An OGTT or a single BG-60 performed at hospital discharge predicts the diagnosis of IGT or diabetes 3 months thereafter.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514578     DOI: 10.2337/diacare.26.10.2770

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  14 in total

1.  [Glucose metabolism].

Authors:  S Eckert; D Tschöpe
Journal:  Z Kardiol       Date:  2005

2.  Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart.

Authors:  M Bartnik; L Rydén; K Malmberg; J Ohrvik; K Pyörälä; E Standl; R Ferrari; M Simoons; J Soler-Soler
Journal:  Heart       Date:  2006-08-11       Impact factor: 5.994

3.  Incidence of Metabolic Syndrome in Patients Admitted to Medical Wards with ST Elevation Myocardial Infarction.

Authors:  Bijilesh Uppalakal; Lekshmi Sankar Karanayil
Journal:  J Clin Diagn Res       Date:  2017-03-01

4.  Screening for undiagnosed diabetes in patients with acute myocardial infarction.

Authors:  Mark Lankisch; Reiner Füth; Hartmut Gülker; Harald Lapp; Alexander Bufe; Burkhard Haastert; Stephan Martin; Wolfgang Rathmann
Journal:  Clin Res Cardiol       Date:  2008-05-19       Impact factor: 5.460

5.  The value of admission glycosylated hemoglobin level in patients with acute myocardial infarction.

Authors:  Mahmut Cakmak; Nazmiye Cakmak; Sebnem Cetemen; Halil Tanriverdi; Yavuz Enc; Onder Teskin; I Dogu Kilic
Journal:  Can J Cardiol       Date:  2008-05       Impact factor: 5.223

Review 6.  The oral glucose tolerance test for the diagnosis of diabetes mellitus in patients during acute coronary syndrome hospitalization: a meta-analysis of diagnostic test accuracy.

Authors:  Yicong Ye; Hongzhi Xie; Xiliang Zhao; Shuyang Zhang
Journal:  Cardiovasc Diabetol       Date:  2012-12-27       Impact factor: 9.951

7.  Value of oral glucose tolerance test in the acute phase of myocardial infarction.

Authors:  Agata Bronisz; Marek Kozinski; Przemyslaw Magielski; Tomasz Fabiszak; Joanna Gierach; Iwona Swiatkiewicz; Adam Sukiennik; Aldona Kubica; Marek Bronisz; Zofia Grabczewska; Anna Sinkiewicz; Roman Junik; Jacek Kubica
Journal:  Cardiovasc Diabetol       Date:  2011-03-11       Impact factor: 9.951

8.  Prevalence, detection, and management of the metabolic syndrome in patients with acute myocardial infarction: role of an obesity-centric definition.

Authors:  Sandhir B Prasad; Farzan Fahrtash; Yuvaraj Malaiapan; Ian T Meredith; James Cameron
Journal:  Cardiol Res Pract       Date:  2010-07-27       Impact factor: 1.866

9.  Impact of newly diagnosed abnormal glucose regulation on long-term prognosis in low risk patients with ST-elevation myocardial infarction: A follow-up study.

Authors:  Eva C Knudsen; Ingebjørg Seljeflot; Michael Abdelnoor; Jan Eritsland; Arild Mangschau; Carl Müller; Harald Arnesen; Geir O Andersen
Journal:  BMC Endocr Disord       Date:  2011-07-29       Impact factor: 2.763

10.  Abnormal glucose regulation in patients with acute ST- elevation myocardial infarction-a cohort study on 224 patients.

Authors:  Eva C Knudsen; Ingebjørg Seljeflot; Michael Abdelnoor; Jan Eritsland; Arild Mangschau; Harald Arnesen; Geir O Andersen
Journal:  Cardiovasc Diabetol       Date:  2009-01-30       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.